Media coverage
3
Media coverage
Title United States : U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet Tendernews.com Country/Territory India Date 9/11/22 URL metabase.moreover.com/noarticleurl?type=psh&lni=66TP-BX31-DYDW-748D-00000-00 Persons Ajai Chari Title United States : U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet TendersInfo – News Country/Territory India Date 8/11/22 URL metabase.moreover.com/noarticleurl?type=psh&lni=66TP-9421-JDJN-64NM-00000-00 Persons Ajai Chari Title United States : U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet Mena Report Country/Territory United Kingdom Date 8/11/22 URL metabase.moreover.com/noarticleurl?type=psh&lni=66TN-WT11-F11P-X3V6-00000-00 Persons Ajai Chari